Should I buy or sell Progyny stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Progyny in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PGNY shares. View PGNY analyst ratings or view top-rated stocks .

What is Progyny's stock price target for 2024?

8 brokers have issued 1-year target prices for Progyny's stock. Their PGNY share price targets range from $34.00 to $57.00. On average, they expect the company's share price to reach $47.00 in the next twelve months. This suggests a possible upside of 29.6% from the stock's current price. View analysts price targets for PGNY or view top-rated stocks among Wall Street analysts .

How have PGNY shares performed in 2023?

Progyny's stock was trading at $31.15 on January 1st, 2023. Since then, PGNY stock has increased by 16.4% and is now trading at $36.26. View the best growth stocks for 2023 here .

When is Progyny's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024. View our PGNY earnings forecast .

How were Progyny's earnings last quarter?

Progyny, Inc. (NASDAQ:PGNY) announced its quarterly earnings data on Tuesday, November, 7th. The company reported $0.16 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.11 by $0.05. The business earned $280.90 million during the quarter, compared to the consensus estimate of $271.20 million. Progyny had a net margin of 5.03% and a trailing twelve-month return on equity of 11.64%. The business's revenue was up 36.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.13 EPS.

What ETFs hold Progyny's stock?

ETFs with the largest weight of Progyny (NASDAQ:PGNY) stock in their portfolio include Alger Weatherbie Enduring Growth ETF (AWEG) , Aztlan Global Stock Selection DM SMID ETF (AZTD) , BNY Mellon Women's Opportunities ETF (BKWO) , SPDR S&P Health Care Services ETF (XHS) , Thrivent Small-Mid Cap ESG ETF (TSME) , Harbor Corporate Culture Small Cap ETF (HAPS) , Nuveen Small Cap Select ETF (NSCS) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) .

What guidance has Progyny issued on next quarter's earnings?

Progyny issued an update on its fourth quarter earnings guidance on Tuesday, November, 7th. The company provided earnings per share (EPS) guidance of $0.10-$0.11 for the period, compared to the consensus EPS estimate of $0.11. The company issued revenue guidance of $268.3-$276.3 million, compared to the consensus revenue estimate of $274.26 million.

What is David Schlanger's approval rating as Progyny's CEO?

25 employees have rated Progyny Chief Executive Officer David Schlanger on Glassdoor.com . David Schlanger has an approval rating of 89% among the company's employees.

What other stocks do shareholders of Progyny own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Progyny investors own include NVIDIA (NVDA) , Alibaba Group (BABA) , Salesforce (CRM) , Marvell Technology (MRVL) , Alteryx (AYX) , Micron Technology (MU) , AbbVie (ABBV) , Home Depot (HD) , Advanced Micro Devices (AMD) .

When did Progyny IPO?

(PGNY) raised $150 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Citigroup, Piper Jaffray, SVB Leerink and TPG Capital were co-managers.

Who are Progyny's major shareholders?

Progyny's stock is owned by a number of institutional and retail investors. Top institutional investors include Clearbridge Investments LLC (4.11%), Fred Alger Management LLC (3.35%), Jennison Associates LLC (2.84%), JPMorgan Chase & Co. (2.56%), Riverbridge Partners LLC (1.97%) and Baillie Gifford & Co. (1.72%). Insiders that own company stock include Beth C Seidenberg, Cheryl Scott , David J Schlanger , Group Holdings (Sbs) Advis Tpg, Jennifer Bealer , Kevin K Gordon , Lisa Greenbaum , Mark S Livingston , Michael E Sturmer , Norman Payson , Perkins Caufield & Bye Kleiner, Peter Anevski , Robert Michael Floyd and Tpg Gp A, Llc. View institutional ownership trends .

How do I buy shares of Progyny?

Shares of PGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Progyny Stock Price, News & Analysis (NASDAQ:PGNY)

$36.26

-0.05 (-0.14%)

(As of 12/8/2023 ET)

Compare

Today's Range: $36.06
▼
$36.96
50-Day Range: $29.51
▼
$36.45
52-Week Range: $28.03
▼
$44.95

Volume: 590,825 shs
Average Volume: 720,179 shs
Market Capitalization: $3.48 billion

P/E Ratio: 69.73
Dividend Yield: N/A
Price Target: $47.00

Progyny MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.88 Rating Score
Upside/Downside: 29.6% Upside
$47.00 Price Target
Short Interest: Bearish
6.87% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.22
Based on 7 Articles This Week
Insider Trading: Selling Shares
$1.30 M Sold Last Quarter
Proj. Earnings Growth: 19.30%
From $0.57 to $0.68 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.92 out of 5 stars

Medical Sector

35th out of 954 stocks

Miscellaneous Health & Allied Services, Not Elsewhere Classified Industry

1st out of 8 stocks

4.4

Analyst's Opinion

Consensus Rating
Progyny has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $47.00, Progyny has a forecasted upside of 29.6% from its current price of $36.26.
Amount of Analyst Coverage
Progyny has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
6.87% of the float of Progyny has been sold short.
Short Interest Ratio / Days to Cover
Progyny has a short interest ratio ("days to cover") of 7.6.
Change versus previous month
Short interest in Progyny has recently increased by 8.21%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Progyny does not currently pay a dividend.
Dividend Growth
Progyny does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PGNY.

2.3

News and Social Media Coverage

News Sentiment
Progyny has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Progyny this week, compared to 3 articles on an average week.
Search Interest
4 people have searched for PGNY on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Progyny to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Progyny insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,301,826.00 in company stock.
Percentage Held by Insiders
14.30% of the stock of Progyny is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
94.93% of the stock of Progyny is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Progyny are expected to grow by 19.30% in the coming year, from $0.57 to $0.68 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Progyny is 69.73, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 119.79.
Price to Earnings Ratio vs. Sector
The P/E ratio of Progyny is 69.73, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 130.78.
Price to Earnings Growth Ratio
Progyny has a PEG Ratio of 1.43. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Progyny has a P/B Ratio of 8.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Progyny Stock (NASDAQ:PGNY)

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

PGNY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PGNY Stock News Headlines

December 8, 2023 | americanbankingnews.com

Progyny, Inc. (NASDAQ:PGNY) President Sells $433,314.48 in Stock

December 7, 2023 | americanbankingnews.com

Mark S. Livingston Sells 25,087 Shares of Progyny, Inc. (NASDAQ:PGNY) Stock

December 9, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

December 4, 2023 | finance.yahoo.com

Returns On Capital Are Showing Encouraging Signs At Progyny (NASDAQ:PGNY)

December 1, 2023 | americanbankingnews.com

Progyny, Inc. (NASDAQ:PGNY) Receives Consensus Recommendation of "Moderate Buy" from Analysts

November 21, 2023 | axios.com

Progyny to birth new products across fertility, repro health

November 20, 2023 | finance.yahoo.com

Does Progyny (PGNY) have a Long Runway for Growth?

November 16, 2023 | seekingalpha.com

Progyny: Market Underappreciating Excellent Quarter

December 9, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

November 15, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Intellia Therapeutics (NTLA), Pfizer (PFE)

November 13, 2023 | finance.yahoo.com

Progyny (PGNY) is an Incredible Growth Stock: 3 Reasons Why

November 10, 2023 | finance.yahoo.com

Progyny, Inc. to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

November 9, 2023 | finance.yahoo.com

Progyny, Inc. (NASDAQ:PGNY) Q3 2023 Earnings Call Transcript

November 8, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Progyny (PGNY), DaVita (DVA) and Demant (OtherWILLF)

November 8, 2023 | markets.businessinsider.com

Analyst Ratings for Progyny

November 7, 2023 | morningstar.com

Progyny Inc PGNY

November 7, 2023 | markets.businessinsider.com

Progyny, Inc. Announces Third Quarter 2023 Results

November 2, 2023 | nasdaq.com

‘The Stage Is Set for a Rally’: Canaccord Sees up to 290% Upside for These 3 Stocks

November 1, 2023 | finance.yahoo.com

The Broken Brown Egg and Progyny Launch 2023 Awareness, Hope, and Activism Grant™ to Help BIPOC Individuals and Couples Expand Their Families

October 31, 2023 | finance.yahoo.com

Earnings Preview: Progyny (PGNY) Q3 Earnings Expected to Decline

October 24, 2023 | finance.yahoo.com

Progyny, Inc. Announces Details for Its Third Quarter 2023 Results Report

October 15, 2023 | seekingalpha.com

Progyny: 4 Reasons I Bought This Stock

October 11, 2023 | finance.yahoo.com

Could The Market Be Wrong About Progyny, Inc. (NASDAQ:PGNY) Given Its Attractive Financial Prospects?

September 28, 2023 | nasdaq.com

Canaccord Genuity Initiates Coverage of Progyny (PGNY) with Buy Recommendation

September 27, 2023 | finance.yahoo.com

Progyny (PGNY): Unveiling Its True Value

September 13, 2023 | benzinga.com

Check Out What Whales Are Doing With PGNY

September 1, 2023 | finance.yahoo.com

3 Reasons Growth Investors Will Love Progyny (PGNY)

See More Headlines

Receive PGNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Progyny and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/07/2023
Today: 12/08/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/26/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Miscellaneous health & allied services, not elsewhere classified
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PGNY
CUSIP: N/A
CIK: 1551306
Web: www.progyny.com
Phone: 212-888-3124
Fax: N/A
Employees: 393
Year Founded: 2008

Price Target and Rating

Average Stock Price Target: $47.00
High Stock Price Target: $57.00
Low Stock Price Target: $34.00
Potential Upside/Downside: +29.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.88
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.52
Trailing P/E Ratio: 69.73
Forward P/E Ratio: 63.61
P/E Growth: 1.43
Net Income: $30.36 million
Net Margins: 5.03%
Pretax Margin: 5.67%
Return on Equity: 11.64%
Return on Assets: 7.99%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.16
Quick Ratio: 3.16

Sales & Book Value

Annual Sales: $1.03 billion
Price / Sales: 3.36
Cash Flow: $0.36 per share
Price / Cash Flow: 100.53
Book Value: $4.06 per share
Price / Book: 8.93

Miscellaneous

Outstanding Shares: 95,836,000
Free Float: 82,419,000
Market Cap: $3.48 billion
Optionable: Not Optionable
Beta: 1.51

Social Links

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mr. David J. Schlanger (Age 64)
Executive Chairman
Comp: $510.41k
Mr. Peter Anevski (Age 56)
CEO & Director
Comp: $1.01M
Mr. Michael Sturmer (Age 46)
President
Comp: $761.5k
Mr. Mark S. Livingston (Age 57)
Chief Financial Officer
Comp: $693.87k
Ms. Allison Swartz (Age 33)
Executive VP, General Counsel & Secretary
Comp: $173.35k
Mr. James Hart
Vice President of Investor Relations
Ms. Risa Fisher
Executive VP & Chief Marketing Officer
Ms. Cassandra Pratt
Senior VP of People
Ms. Julie Stadlbauer
Executive Vice President of Strategic Sales & Partnerships
Ms. Janet Choi M.D.
Member of the Medical Advisory Board & Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PGNY Stock Analysis - Frequently Asked Questions

Should I buy or sell Progyny stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Progyny in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PGNY shares.
View PGNY analyst ratings or view top-rated stocks.
What is Progyny's stock price target for 2024?: 8 brokers have issued 1-year target prices for Progyny's stock. Their PGNY share price targets range from $34.00 to $57.00. On average, they expect the company's share price to reach $47.00 in the next twelve months. This suggests a possible upside of 29.6% from the stock's current price.
View analysts price targets for PGNY or view top-rated stocks among Wall Street analysts.
How have PGNY shares performed in 2023?: Progyny's stock was trading at $31.15 on January 1st, 2023. Since then, PGNY stock has increased by 16.4% and is now trading at $36.26.
View the best growth stocks for 2023 here.
When is Progyny's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our PGNY earnings forecast.
How were Progyny's earnings last quarter?: Progyny, Inc. (NASDAQ:PGNY) announced its quarterly earnings data on Tuesday, November, 7th. The company reported $0.16 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.11 by $0.05. The business earned $280.90 million during the quarter, compared to the consensus estimate of $271.20 million. Progyny had a net margin of 5.03% and a trailing twelve-month return on equity of 11.64%. The business's revenue was up 36.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.13 EPS.
What ETFs hold Progyny's stock?: ETFs with the largest weight of Progyny (NASDAQ:PGNY) stock in their portfolio include Alger Weatherbie Enduring Growth ETF (AWEG), Aztlan Global Stock Selection DM SMID ETF (AZTD), BNY Mellon Women's Opportunities ETF (BKWO), SPDR S&P Health Care Services ETF (XHS), Thrivent Small-Mid Cap ESG ETF (TSME), Harbor Corporate Culture Small Cap ETF (HAPS), Nuveen Small Cap Select ETF (NSCS) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).

What guidance has Progyny issued on next quarter's earnings?: Progyny issued an update on its fourth quarter earnings guidance on Tuesday, November, 7th. The company provided earnings per share (EPS) guidance of $0.10-$0.11 for the period, compared to the consensus EPS estimate of $0.11. The company issued revenue guidance of $268.3-$276.3 million, compared to the consensus revenue estimate of $274.26 million.
What is David Schlanger's approval rating as Progyny's CEO?: 25 employees have rated Progyny Chief Executive Officer David Schlanger on Glassdoor.com. David Schlanger has an approval rating of 89% among the company's employees.
What other stocks do shareholders of Progyny own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Progyny investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Marvell Technology (MRVL), Alteryx (AYX), Micron Technology (MU), AbbVie (ABBV), Home Depot (HD), Advanced Micro Devices (AMD).
When did Progyny IPO?: (PGNY) raised $150 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Citigroup, Piper Jaffray, SVB Leerink and TPG Capital were co-managers.
Who are Progyny's major shareholders?: Progyny's stock is owned by a number of institutional and retail investors. Top institutional investors include Clearbridge Investments LLC (4.11%), Fred Alger Management LLC (3.35%), Jennison Associates LLC (2.84%), JPMorgan Chase & Co. (2.56%), Riverbridge Partners LLC (1.97%) and Baillie Gifford & Co. (1.72%). Insiders that own company stock include Beth C Seidenberg, Cheryl Scott, David J Schlanger, Group Holdings (Sbs) Advis Tpg, Jennifer Bealer, Kevin K Gordon, Lisa Greenbaum, Mark S Livingston, Michael E Sturmer, Norman Payson, Perkins Caufield & Bye Kleiner, Peter Anevski, Robert Michael Floyd and Tpg Gp A, Llc.
View institutional ownership trends.
How do I buy shares of Progyny?: Shares of PGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:PGNY) was last updated on 12/9/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial